Active, not recruitingPhase 2NCT03851614

Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors

Studying Leiomyosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Health Network, Toronto
Principal Investigator
Lillian Siu, MD
Princess Margaret Cancer Centre
Intervention
Durvalumab(biological)
Enrollment
90 target
Eligibility
18 years · All sexes
Timeline
2019 – 2027

Study locations (1)

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03851614 on ClinicalTrials.gov

Other trials for Leiomyosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Leiomyosarcoma →

← Back to all trials